Public Company Edition: This year’s newly public companies are trading an average of 9.7% below their IPO prices, including the two most recent debuts, Boundless Bio and Contineum. Also, Nkarta, Praxis and Nurix grossed $240m, $200m and $175m, respectively, in follow-on offerings.

Plus deals involving Biocytogen/Radiance, Maruho/AOBiome, LGChem/Rhythm, IASO/Umoja, JW Therapeutics/2seventy and 13 other transactions.

In Vivo talks to investors, analysts and companies in rare disease about the challenges they face to innovate and to grow.

Despite the astounding efficacy and commercial potential of incretins in obesity, many groups are trying different mechanistic approaches to the disease – if only to enable combinations.